We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s price watchdog is recommending Bayer’s eye medicine Eylea as a first-line treatment for vision loss due to fluid buildup in the retina, provided the company discounts its price. Read More
Lawmakers have called on the Department of Justice to investigate whether Mylan violated the law by misclassifying its severe allergy treatment EpiPen as a generic in the Medicaid Drug Rebate Program. Read More
Despite significant potential savings in time and money, drug and medical device manufacturers have been slow to embrace continuous manufacturing, an FDA technology official said. Read More
The FDA is looking to increase its post-marketing inspections of manufacturing facilities, mainly within six months to two years after an approval, focused on ensuring that quality is maintained after a company scales up to commercial production. Read More
Kite Pharma announced positive interim results from a Phase II clinical trial of its immunotherapy in patients with aggressive non-Hodgkin’s lymphomas, and said the study would form the basis of its marketing submissions to the FDA. Read More
The Indian government has revised its list of essential medicines, removing price caps on dozens of drugs in a number of therapeutic classes. Read More
Cheng Fong Chemical received a warning letter from the FDA for dirty equipment, poorly maintained facilities and improper investigations into possibly tainted batches of active pharmaceutical ingredients. Read More